drugset / Trial / NCT00982631

A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer

NCT00982631

Phase 1 Unknown 30 enrolled Radboud University Medical Center
NaSingle-groupOpen-labelTreatment

Summary

A study to examine the combination of temsirolimus and Caelyx® (chemotherapeutic) in advanced or recurrent breast, endometrial and ovarian cancer.

Timeline

Start
2009-06
Primary completion
2012-02
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified
Subject Temsirolimus Small molecule Intravenous